Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

A user has been taking finasteride 1mg for 10 years without side effects but is concerned about high estradiol levels affecting weight loss. Another user suggests using estradiol blockers under medical supervision to manage the levels.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

AB-103, a minoxidil sulfotransferase stimulant, is discussed as a potential hair loss treatment. Users inquire about effective boosters for hair growth.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

A user is considering dutasteride mesotherapy versus oral finasteride for hair loss, with concerns about side effects. Other users share experiences with both treatments, suggesting oral finasteride as more effective and cost-efficient, while also discussing the use of minoxidil, alfatradiol, and potential side effects like gynecomastia.

Young individuals with seemingly healthy hairlines are using treatments like finasteride, dutasteride, and minoxidil, possibly due to paranoia or proactive prevention of hair loss. Some believe social media influences this behavior, while others argue for waiting until actual hair loss begins before starting treatment.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.

Stemoxydine's effects on hair growth are uncertain and not well-studied, with users reporting mixed results and concerns about maintaining gains. Some users combine it with 5AR inhibitors like Dutasteride, but results vary, and conditions like lichen planopilaris complicate treatment.

The user experienced hair shedding after increasing minoxidil from 5% to 7% with latanoprost, possibly causing telogen effluvium. They are on HRT with Lupron, Estradiol, and Raloxifene, and are concerned about the shedding's duration.

Minoxidil and finasteride are discussed for hair loss, with concerns about minoxidil's heart-related side effects. New treatments like PP405 are met with skepticism, often humorously noted as always being "five years away."

A new stem cell therapy shows promise in treating hair loss, but skepticism remains about its availability. Users humorously discuss the effectiveness of treatments on mice compared to humans.

The conversation discusses whether not masturbating (semen retention) affects hair loss, with opinions varying but generally dismissing the idea. Some participants mention using hair loss treatments like Minoxidil, Finasteride, and RU58841, but the effectiveness and relation to prolactin levels in the scalp are debated.

A 51-year-old on TRT plans to use steroids and is concerned about hair loss, considering topical treatments like Hair Rescue with RU58841 and finasteride, along with Nioxin shampoo. They are cautious about using oral DHT blockers due to potential interactions with steroids like Tren and Anavar.

Balancing hormones, particularly testosterone and DHT, may prevent hair loss and slow aging. Treatments include finasteride, dutasteride, zinc, magnesium, collagen, and natural DHT-blocking shampoos.

A manager told an employee to stop using minoxidil, fearing it could unintentionally cause hair growth in others. The conversation is filled with humorous and sarcastic responses, questioning the manager's logic and suggesting the employee continue using the treatment secretly.

The user switched from topical to oral finasteride and minoxidil for hair loss and experienced swelling and sensitivity in the left chest area. They are concerned about these symptoms but noticed improvement after skipping a dose.

A 43-year-old experienced gynecomastia after 20 years of taking dutasteride and 7.5mg oral minoxidil. Suggestions include consulting an endocrinologist, checking hormones, and considering Nolvadex or DIM supplements.

A 17-year-old experienced significant hair loss after switching from topical to oral minoxidil and adding finasteride. The recommendation is to return to topical minoxidil and continue with finasteride or consider dutasteride.

The conversation discusses using Botox to treat male pattern baldness, suggesting it may promote hair growth by increasing scalp blood flow and oxygen, reducing dihydrotestosterone levels. The user wonders why this treatment is not widely discussed or if it has been discredited.

A user underwent a hair transplant at Moart Clinic in Seoul, receiving 1100 grafts in the crown area after Dutasteride and oral Minoxidil failed to improve a stubborn bald spot. The procedure was successful, with minimal pain and good post-op recovery, costing $6900 USD before a tax refund.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

The conversation discusses the importance of scalp biopsies for diagnosing hair loss conditions like DUPA and Retrograde, which may not be just AGA. It emphasizes that treatments like finasteride and dutasteride may not work if the condition is autoimmune.

The conversation discusses the anticipation and skepticism around the release of GT20029 for hair loss treatment. The original poster has been using Finasteride and Minoxidil but is hopeful for GT20029, while others express doubts about its timely release and suggest alternatives like KX826 and hair transplants.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. Concerns about AI-generated content accuracy and misinformation are raised.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

A 23-year-old male experienced initial success with finasteride, topical minoxidil, and ketoconazole for hair loss, but persistent shedding and scalp issues led him to switch to dutasteride without improvement. Users suggest stress management, addressing potential seborrheic dermatitis, and patience with the treatment process.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.